Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 1997

View Archived Issues

DepoTech: Q3 1997 highlights

Penwest: Q4 and FY 1997 highlights

Kyowa Hakko: Annual Report 1997

Tripos: Q3 1997 highlights

Antitumor effects of Techniclone's LYM-2 reported

FDA clears generic estradiol product

Lilly and Chugai enter into combinatorial chemistry collaboration

Apligraf comparable to autograft for donor site wounds

Diester prodrugs of antiviral acyclic nucleoside disclosed by Medivir

Biomeasure discloses protein farnesyltranserase inhibitors

Endothelin antagonists described by Bristol-Myers Squibb

New serine protease inhibitors for thrombotic disorders from Akzo Nobel

Shionogi presents potent and selective CCKB/gastrin receptor antagonist

Effects of NO donor ITF-1129 on blood flow/hemodynamics during myocardial ischemia

Advisory committee recommends approval for Plavix

Banyu discloses protein farnesyltransferase inhibitors

New ACAT inhibitors discovered at Mitsubishi Chemical

Update on Sano product pipeline

Pravachol now available in Canada for preventing a first heart attack

Differin is equieffective but better tolerated than Retin A in patients with acne

Bicalutamide + LHRH-A vs. flutamide + LHRH-A for metastatic prostate cancer

Hepatitis C-related technology available for licensing from NIH

Lyme disease diagnostic technology available for licensing

MuLV diagnostic kit available from NIH

FDA clears generic cimetidine

Gene therapy approach to preventing organ transplant complication explored

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...